US experts review heart attack risk of GlaxoSmithKline’s diabetes drug
WASHINGTON:Â GlaxoSmithKline’s controversial diabetes drug Avandia, restricted in the US and banned in Europe over concerns it raises heart attack risk, is getting a second look...